anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: In response to the global scope of forced displacement, international organizations highlight the need of scalable solutions to support individuals' health and integration into host societies. Exposure to high mental and physical stress perceived before, during, and after displacement can impair functional capabilities, essential for adapting to a new environment. This secondary analysis examined the impact of an exercise and sport intervention on cognitive function and pain severity among individuals living in a refugee camp in Greece.
METHODS: We implemented a randomized controlled trial involving n = 142 (52.8% women) forcibly displaced individuals from Southwest Asia and Sub-Saharan Africa. Participants were randomly assigned to a waitlist or a 10-week co-designed exercise and sport intervention with a 1:1 allocation rate between groups and sexes. Assessments at baseline and follow-up included the Flanker task, the Oddball paradigm, pain severity via visual analog scales, and the Åstrand-Rhyming indirect test of maximal oxygen uptake. We analyzed the intervention effects using structural equation modeling.
RESULTS: Our findings did not indicate a direct intervention effect on cognitive function or pain (p ≥ .332). However, the intervention group significantly improved cardiorespiratory fitness, ß = .17, p = .010, which was associated with faster reaction times in cognitive tasks, ß =  - .22, p = .004. Moreover, there was some evidence that adherence might be linked to reduced pain severity, ß =  - .14, p = .065.
CONCLUSIONS: Exercise and sport did not directly impact cognitive function and pain severity among a sociodemographically diverse sample living in a refugee camp, suggesting the need for complementary measures. Nevertheless, our results indicate that improvements in cardiorespiratory fitness benefit aspects of attention.
TRIAL REGISTRATION: The study was approved by the local ethics committee of the University of Thessaly (no. 39) and registered prospectively on February 8, 2021 at the ISRCTN registry (no. 16291983).
PURPOSE: Congenital posteromedial bowing (CPMB) of tibia is a rare, usually self-resolving condition that is present at birth. The data on the long-term outcome of lengthening, choice of fixator, outcome in early and late age groups, and complications is sparse, hence the need for this study.
METHODS: This retrospective study included 93 patients with 94 affected legs from 1991 to 2023. The patients were categorized into early (under 10 years) and late (10 years or above) intervention groups. Eighteen patients with nineteen lengthening episodes who attained skeletal maturity made the basis of this study and will be discussed in detail.
RESULTS: The outcome for the lengthening group at maturity was satisfactory, with 5.53 cm of average length gained per lengthening episode, a mean LLD of 0.31 cm at final follow-up, a mean age of 23.63 years (range 14-38 years), and an average follow-up of 12.51 years (range 3-28 years) post-lengthening, but the procedure was associated with difficulties like ankle stiffness, tibial valgus, pin tract infections, and fractures through regenerate.
CONCLUSION: This study represents a large single-centre series on CPMB. We recommend that surgery for lengthening should be done at an older age, close to skeletal maturity, wherever possible to reduce the risk of repeat lengthening procedures. Based on our experience, we recommend the use of a circular fixator. Uniplanar distractors should have an adequate number and spread of Schanz screws in each segment to reduce the risk of valgus malalignment of distracting segments of bone.
Dosage must be individualized. For children who can swallow tablets, the usual recommended starting dose of olmesartan medoxomil tablets is 10 mg once daily for patients who weigh 20 to <35 kg (44 to 77 lb), or 20 mg once daily for patients who weigh ≥35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of olmesartan medoxomil tablets may be increased to a maximum of 20 mg once daily for patients who weigh <35 kg or 40 mg once daily for patients who weigh ≥35 kg.

Use of olmesartan medoxomil tablets in children <1 year of age is not recommended [see Warnings and Precautions (5.2)and Use in Specific Populations (8.4)] . 

For children who cannot swallow tablets, the same dose can be given using an extemporaneous suspension as described below [see Clinical Pharmacology (12.3)] . Follow the suspension preparation instructions below to administer Olmesartan medoxomil tablets as a suspension. 

Preparation of Suspension (for 200 mL of a 2 mg/mL suspension)

Add 50 mL of Purified Water to an amber polyethylene terephthalate (PET) bottle containing twenty Olmesartan medoxomil 20 mg tablets and allow to stand for a minimum of 5 minutes. Shake the container for at least 1 minute and allow the suspension to stand for at least 1 minute. Repeat 1-minute shaking and 1-minute standing for four additional times. Add 100 mL of ORA-Sweet ®and 50 mL of ORA-Plus ®*to the suspension and shake well for at least 1 minute. The suspension should be refrigerated at 2°C to 8°C (36°F to 46°F) and can be stored for up to 4 weeks. Shake the suspension well before each use and return promptly to the refrigerator.   
  
*ORA-Sweet ®and ORA-Plus ®are registered trademarks of Paddock Laboratories, Inc.
Lymphedema is a chronic and debilitating condition characterized by an abnormal buildup of protein-rich fluid in the interstitial tissue, leading to the development of edema and tissue structural alterations. Breast cancer-related lymphedema (BCRL) remains a significant healthcare burden because it can develop within days and up to 11-years after the surgery. Specifically, axillary lymph node dissection leads to 30-50 % upper limb lymphedema, which involves the accumulation of protein-rich fluid. In this article, we provide a comprehensive/critical overview of post-mastectomy lymphedema, focusing on key aspects as diagnosis, prevention, and treatment methods. Beginning with clinical condition, the article explores the pathophysiology and risk factors associated with post-mastectomy lymphedema. It further delves into various diagnostic modalities available, highlighting the importance of early detection for optimal management of BCRL. We also examine preventive strategies, emphasizing the role of patient education, lifestyle modifications, and proactive measures in reducing the risk of lymphedema development. In terms of treatment, the article covers a wide array of interventions ranging from conservative approaches like manual lymphatic drainage and compression therapy to surgical techniques such as lymph node transfer and lymphaticovenular anastomosis. Thus, through a comprehensive synthesis of current evidence and clinical practices updates, the review aims to guide healthcare professionals in delivering preventive and effective care while improving outcomes for individuals affected by post-mastectomy lymphedema.
BACKGROUND: The anti-cancer agent 2-methoxyestradiol (2-ME) has been shown to have anti-proliferative and anti-angiogenic properties. Previously, the effect of 2-ME on early- and late-stage breast cancer (BC) was investigated in vivo using a transgenic mouse model (FVB/N-Tg(MMTV-PyVT)) of spontaneous mammary carcinoma. Anti-tumor effects were observed in late-stage BC with no effect on early-stage BC. Given the contrasting results obtained from the different BC stages, we have now investigated the effect of 2-ME when administered before the appearance of palpable tumors.
METHODS: Each mouse received 100 mg/kg 2-ME on day 30 after birth, twice per week for 28 days, while control mice received vehicle only. Animals were terminated on day 59. Lung and mammary tissue were obtained for immunohistochemical analysis of CD163 and CD3 expression, and histological examination was performed to analyze tumor necrosis. Additionally, blood samples were collected to measure plasma cytokine levels.
RESULTS: 2-ME increased tumor mass when compared to the untreated animals (p = .0139). The pro-tumorigenic activity of 2-ME was accompanied by lower CD3+ T-cell numbers in the tumor microenvironment (TME) and high levels of the pro-inflammatory cytokine interleukin (IL)-1β. Conversely, 2-ME-treatment resulted in fewer CD163+ cells detectable in the TME, increased levels of tumor necrosis, increased IL-10 plasma levels, and low IL-6 and IL-27 plasma levels.
CONCLUSION: Taken together, these findings suggest that 2-ME promotes early-stage BC development.
Elevated corticosteroid level to meet physiologic needs during acute illness is a protective response for stress. This homeostasis is maintained by the hypothalamic-pituitary-adrenal (HPA) axis. However, inadequate response as corticosteroid insufficiency in critically ill patients is reported with increasing frequency, especially in severe sepsis and septic shock. Thus, corticosteroids could be beneficial for septic shock or severe acute illness.

Once considered as normal adrenal function, adrenal insufficiency may developed later with chronic critical illness as adrenal exhaustion syndrome. It is easily overlooked and is possible due to the chronic secretion of systemic cytokines or other HPA axis-suppressive substances. There is still no consensus how often adrenal function testing should be repeated, although a re-evaluation should be considered if clinical symptoms and signs suggest adrenal insufficiency or deteriorating clinical condition.
Healthcare Formulations, Including, Inventive Surfactants, Active Ingredient Formulated As Solids, Liquids, Or Emulsions. The Present Disclosure Provides Formulations Of Healthcare Products, Such As: Prescription Drugs, Over The Counter Drugs; Minerals, Herbal, And/Or Vitamin Supplements; Drugs Administered In Hospitals, Clinics, Physician?s Office, And Places Of Palliative Care; Vaccines, Tissue, Organ, And Cell Transplants And/Or Grafts And/Or Infusions; And Wound Care Formulations Including Topical Ointments, Lotions, Cleaners, Wipes, Bandages, And Dressings. The Active May Be Included In The Formulations As A Solute, A Solvent, A Particle, Or An Oil Immiscible Component Of The Formulation. The Active May Be Included In Tablets, Capsules, Tinctures, Liquids, Or Emulsions. Inventive Healthcare Formulations Include Formulations Suitable For Administration Orally, Topically, And/Or By Injection.   The Most Suitable Drawing: FIG. 1
Recurrent urinary tract infections (rUTIs) are a common condition with high morbidity and negatively impact the quality of life. They account for approximately 25% of all antibiotic prescriptions and are a public health concern in an era of increasing multidrug-resistant organisms (MDROs). Several non-antibiotic treatment strategies have been tried to curb antimicrobial use, and many are effective to some degree, but no experience testing multimodal interventions. We created a "care bundle" consisting of behavioral interventions, vaginal and oral probiotics, D-mannose, and cranberry to be followed for six months. We enrolled women with rUTIs over three years. Changes in urinary tract infections, antibiotic use, chronic symptoms, and quality of life were compared in the six months before and after participation in the study. Forty-seven women were enrolled in the study, six of whom were excluded from the final analysis. We observed a 76% reduction in urinary tract infections (p < 0.001) and a reduction in total antibiotic exposure of more than 90% (p < 0.001); all chronic symptoms showed a trend toward reduction. Adherence to the bundle was high (87.2%). Overall, 80.5% of women experienced an improvement in their quality of life. In our experience, a bundle protocol is effective in reducing recurrences and antimicrobial use in a cohort of women with rUTIs and results in a subjective improvement in chronic symptoms and quality of life. Further research with larger sample size is needed to confirm these findings.
The threat of multidrug-resistant organisms (MDROs) and antimicrobial resistance (AMR) are real and increasing every day. They affect not only healthcare systems but also communities, causing economic and public health concerns. Governments must take action to tackle AMR and prevent the spread of MDROs and regional hubs have a critical role to play in achieving this outcome. Furthermore, bacteria have no borders, consequently, cooperation networks should be extended between countries as a crucial strategy for achieving the success of infection control. Euregions, which are a specific form of cooperation between local authorities of two or more bordering European countries, can help solve common problems and improve the lives of people living on both sides of the border. Regional collaboration strategies can enhance infection control and build resilience against antimicrobial resistance. This review identifies risk factors and the correct approaches to infection prevention and control, including education and awareness programs for healthcare professionals, appropriate prescribing practices, and infection prevention control measures. These measures can help reduce the incidence of antimicrobial resistance in the region and save lives. It is therefore essential to take concrete actions and foster the creation of more effective regional and cross-border centers to ensure the success of infection control policies and the management of healthcare-associated infections. This work sheds light on the issue of MDRO infections within healthcare settings, while also acknowledging the crucial role of the One Health concept in understanding the broader context of these infections. By recognizing the interdependence of human and animal health and the environment, we can take constructive steps toward mitigating the risks of these infections and promoting better health outcomes for all.
PURPOSE:To provide the titled cosmetic consisting of a composition obtained by dispersing cosmetic powder in a volatile aqueous solvent and having improved feeling to the skin, applicability, cosmetic effect, and durability, when sprayer to face after the application of make-up cosmetic. CONSTITUTION:A powdery cosmetic such as extender pigment, white pigment, coloring pigment, organic powder, pearlecent pigment, dye, etc. is dispersed in a volatile aqueous solvent such as water and/or ethanol, etc., in an amount of 0.1-5wt%, and the obtained composition is filled in an aerosol container. The composition is sprayed to the face after the application of make-up cosmet ic. It has excellent application characteristics such as easy and uniform applica bility and pleasant feeling to the skin. An excellent cosmetic effect can be imparted, the make-up can be adjusted easily, and the color and body of the applied cosmetic can be controlled or improved easily. The durability of the cosmetic effect of the make-up can be improved by adding 0.01-1 wt% anhi drotic astringent to the composition.
The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Hypertension is indeed a significant public health concern in Pakistan. Hypertension drastically affects 18.9% of adolescents of age greater than 15 and 33% of adults of age above 45. Uncontrolled blood pressure (BP) is a leading risk factor for major hypertensive complications. In Pakistan, suboptimal adherence to medication remains a stumbling block to the success of antihypertensive treatment. A majority of the population in Pakistan on treatment is found to be non-adherent. mHealth is quite an apt tool positioned to counter these challenges of poor adherence in resource limit settings like Pakistan. What is available is too little to establish any causal relationship. The aim of this study is to assess the effectiveness of mHealth intervention by using a reminder module in improving patient medication adherence in hypertensive patients. The intervention was designed to improve the hypertension-related adherence in participants in the intervention group. The module will be developed and undergone via the process of consultations from a group of experts. These will include professors of epidemiology, one expert in behavioral intervention, two professors of health education, and one cardiologist specialist in hypertension management. For the intervention group, a "multifaceted educational reminder module" will be developed and delivered through "WhatsApp" (written message, voice message, and Graphic-based Reminder (GBR)) by an Information and Technology (IT) facilitator. This will be included daily notes for medication reminders, voice messages,s and Graphic-based Reminders (GBR), Twice-weekly Graphic based Messages(GBM), Lifestyle changing video, hypertension at a glance, and doctor support in addition to the standard care (as per being practiced routinely in the hospitals). WhatsApp is used in this study because of its feature of ticks, which turns out to blue after seeing the message and it is an indication to the sender if the receiver has seen the message, so, the participants no longer need to respond to calls or messages. If the intervention is found effective, it can help in developing educational guidelines for patients to improve their medication adherence and reduce related complications at the same time. This study will give a new line of research for coming researchers in the long run. Moreover, its cost-effectiveness will be assessed to predict one dollar bring about improvement per mmHg.
PURPOSE:To obtain the titled cosmetic having improved separability and separation restorability caused by the salting-out effect of soluble electrolyte, by adding an anionic surfactant to hair cosmetic containing relatively small amount of a surfactant composed mainly of cationic surfactant. CONSTITUTION:The objective separation-type hair cosmetic is composed of (A) 0.1-10wt% (based on the whole components of the hair cosmetic) cationic surfactant of preferably formula I (R1 is 10-24C alkyl, etc.; R2-R4 are 1-3C alkyl, etc.; X is halogen, etc.) and an anionic surfactant of preferably formula II (R6 is 1-22C straight-chain, alkyl, etc.; R7 is H or CH3; Y is H, alkali metal, etc.; n is integer of 0-100; X is group of formula III or Y), etc., and (B) a layer of an aqueous solution of an soluble electrolyte containing 1-20wt% soluble electrolyte, preferably alkali metal salt or alkaline earth metal salt of inorganic acid. The cosmetic has excellent layer-forming property, quickly separates into layers after use and has excellent separation restorability and high storage stability.
The toxic dose of barbiturates varies considerably. In general, an oral dose of 1 gram of most barbiturates produces serious poisoning in an adult. Death commonly occurs after 2 to 10 grams of ingested barbiturate. Barbiturate intoxication may be confused with alcoholism, bromide intoxication, and with various neurological disorders. 

Acute overdosage with barbiturates is manifested by CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may show paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur. 

In extreme overdose, all electrical activity in the brain may cease, in which case a “flat” EEG normally equated with clinical death cannot be accepted. This effect is fully reversible unless hypoxic damage occurs. Consideration should be given to the possibility of barbiturate intoxication even in situations that appear to involve trauma. 

Complications such as pneumonia, pulmonary edema, cardiac arrhythmias, congestive heart failure, and renal failure may occur. Uremia may increase CNS sensitivity to barbiturates. Differential diagnosis should include hypoglycemia, head trauma, cerebrovascular accidents, convulsive states, and diabetic coma. Blood levels from acute overdosage for some barbiturates are listed in Table 1. 

Treatment of overdosage is mainly supportive and consists of the following: 

  1. Maintenance of an adequate airway, with assisted respiration and oxygen administration as necessary. 
  2. Monitoring of vital signs and fluid balance. 
  3. Fluid therapy and other standard treatment for shock, if needed. 
  4. If renal function is normal, forced diuresis may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital, also aprobarbital and mephobarbital (which is metabolized to phenobarbital). 
  5. Although not recommended as a routine procedure, hemodialysis may be used in severe barbiturate intoxications or if the patient is anuric or in shock. 
  6. Patient should be rolled from side to side every 30 minutes. 
  7. Antibiotics should be given if pneumonia is suspected. 
  8. Appropriate nursing care to prevent hypostatic pneumonia, decubiti, aspiration, and other complications of patients with altered states of consciousness.
PURPOSE: A composition using Phlomis umbrosa Turcz. extract and Polygala tenuifolia Willd. extract for preventing or treating insomnia is provided to normally recover sleep state. CONSTITUTION: A composition for preventing or treating insomnia contains Polygala tenuifolia Willd. extract, Phlomis umbrosa Turcz. extract or mixture as an active ingredient. The extract is obtained using water, hydrous and anhydrous low alcohol of 1-4 carbon atoms(methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol and normal-butanol), mixture solvent of low alcohol and water, acetone, ethyl acetate, chloroform, 1,3-butylene glycol, hexane or diethyl ether.
FIELD: medicine, gynecology. SUBSTANCE: after adhesiolysis and restoration of passability of uterine tubes one should wash out the cavity of small pelvis with ozonized physiological solution at 5-6 mg/l. On the 1st -2nd d of postoperative period one should carry out seances of curative plasmapheresis in interrupted mode at 2-4 seances at 2-d-long interval. Simultaneously, it is necessary to perform intravenous injection of ozonized physiological solution by drops at 2 mg/l for 5 seances. On the 5th -7th d of postoperative period curative hydrotubation should be conducted with ozonized physiological solution at 0.5 mg/l under control of transvaginal hysterosalpingoechography. Hydrotubation should be repeated in 1-2 mo. The suggested innovation decreases possibility for adhesive process in small pelvic cavity. EFFECT: higher efficiency of therapy. 2 ex
Once weekly sessions of slip recovery training for 3 or 6 weeks. Each session will be 20 minutes of training. Training will involve volitional and reactive stepping movements that mimic the movements necessary to recover balance after slipping while walking.
Systems and methods for providing a built-in training capability for a computer application associated with multiple operations. A control icon may be presented along with an image associated with the particular computer application. The control icon may list training tasks that are associated with the particular computer application or the particular image and train a user in performing a particular operation. Based upon a user interaction with the control icon, a training task may be implemented. The training task may comprise multiple steps or actions required to complete the task. The training task may cause a written description of each action and a training icon to be presented to the user. The training task may therefore assist the user in performing the operation associated with the training task.
Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.